Home LiteratureArticle Details
PMID: 17582453 Published · ppublish English Journal Article Research Support, N.I.H., Extramural

Differential functional phenotypes of two primary HIV-1 strains resulting from homologous point mutations in the LLP domains of the envelope gp41 intracytoplasmic domain.

Virology ·Vol. 367 ·No. 1 ·2007-10-10 ·Pages 102-16

Newman JT, Sturgeon TJ, Gupta P, Montelaro RC

Abstract

We previously reported that selected mutations of highly conserved arginine residues within the LLP regions of HIV-1(ME46) gp41 had diverse effects on Env function. In the current study, we sought to test if the observed LLP mutant phenotypes would be similar in HIV-1(89.6). The results of the current studies revealed that the LLP-1 mutations conferred reduced Env incorporation, infectivity, and replication phenotypes in both viruses, while homologous LLP-2 mutations had differential phenotypical effects between the two strains. In particular, several of the 89.6 LLP-2 mutant viruses were replication defective in CEMX174 cells despite having increased levels of Env incorporation, and with both strains, there were differential effects on infectivity. This comparison of homologous point mutations in two different strains of HIV supports the role of LLPs as determinants of Env function, but reveals for the first time the influence of virus strain on LLP mutant phenotypes.

MeSH Terms
Amino Acid Sequence Animals Cell Fusion Gene Expression Regulation, Viral Gene Products, env/genetics,metabolism HIV Envelope Protein gp41/chemistry,genetics HIV-1/classification,genetics,metabolism,pathogenicity Humans Molecular Sequence Data Peptide Fragments/chemistry,genetics Phenotype Point Mutation Virus Replication
Chemicals
Gene Products, env HIV Envelope Protein gp41 Peptide Fragments lentiviral lytic peptide type 1, Human immunodeficiency virus 1
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Newman Jason T
Department of Molecular Genetics and Biochemistry, School of Medicine, University of Pittsburgh, PA 15261, USA.
Sturgeon Timothy J
Gupta Phalguni
Montelaro Ronald C
References (90)
90 references, click to expand
  1. Live, attenuated simian immunodeficiency virus SIVmac-M4, with point mutations in the Env transmembrane protein intracytoplasmic domain, provides partial protection from mucosal challenge with pathogenic SIVmac251.
    J Virol. 2002 Nov;76(22):11365-78 PMID: 12388697
  2. A region of the C-terminal tail of the gp41 envelope glycoprotein of human immunodeficiency virus type 1 contains a neutralizing epitope: evidence for its exposure on the surface of the virion.
    J Gen Virol. 2003 Mar;84(Pt 3):591-602 PMID: 12604810
  3. Rational site-directed mutations of the LLP-1 and LLP-2 lentivirus lytic peptide domains in the intracytoplasmic tail of human immunodeficiency virus type 1 gp41 indicate common functions in cell-cell fusion but distinct roles in virion envelope incorporation.
    J Virol. 2003 Mar;77(6):3634-46 PMID: 12610139
  4. Targeting of the human immunodeficiency virus type 1 envelope to the trans-Golgi network through binding to TIP47 is required for env incorporation into virions and infectivity.
    J Virol. 2003 Jun;77(12):6931-45 PMID: 12768012
  5. A novel monoclonal antibody specific to the C-terminal tail of the gp41 envelope transmembrane protein of human immunodeficiency virus type 1 that preferentially neutralizes virus after it has attached to the target cell and inhibits the production of infectious progeny.
    Virology. 2003 Oct 25;315(2):362-72 PMID: 14585339
  6. Regulation of human immunodeficiency virus type 1 Env-mediated membrane fusion by viral protease activity.
    J Virol. 2004 Jan;78(2):1026-31 PMID: 14694135
  7. The membrane-proximal tyrosine-based sorting signal of human immunodeficiency virus type 1 gp41 is required for optimal viral infectivity.
    J Virol. 2004 Feb;78(3):1069-79 PMID: 14722262
  8. Coupling of human immunodeficiency virus type 1 fusion to virion maturation: a novel role of the gp41 cytoplasmic tail.
    J Virol. 2004 Apr;78(7):3429-35 PMID: 15016865
  9. Modulation of Env content in virions of simian immunodeficiency virus: correlation with cell surface expression and virion infectivity.
    J Virol. 2004 Jul;78(13):6775-85 PMID: 15194752
  10. Genes regulating HLA class I antigen expression in T-B lymphoblast hybrids.
    Immunogenetics. 1985;21(3):235-46 PMID: 3872841
  11. Aberrant Gag protein composition of a human immunodeficiency virus type 1 vif mutant produced in primary lymphocytes.
    J Virol. 1995 Jul;69(7):4582-6 PMID: 7769728
  12. Endocytosis of endogenously synthesized HIV-1 envelope protein. Mechanism and role in processing for association with class II MHC.
    J Immunol. 1995 Jul 1;155(1):473-88 PMID: 7602119
  13. Effect of amino acid substitutions on calmodulin binding and cytolytic properties of the LLP-1 peptide segment of human immunodeficiency virus type 1 transmembrane protein.
    J Virol. 1995 Aug;69(8):5199-202 PMID: 7609094
  14. Domains of the human immunodeficiency virus type 1 matrix and gp41 cytoplasmic tail required for envelope incorporation into virions.
    J Virol. 1996 Jan;70(1):341-51 PMID: 8523546
  15. A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors.
    Cell. 1996 Jun 28;85(7):1149-58 PMID: 8674120
  16. Restricted antigenic variability of the epitope recognized by the neutralizing gp41 antibody 2F5.
    AIDS. 1996 Jun;10(6):587-93 PMID: 8780812
  17. Human immunodeficiency virus type 1 envelope protein endocytosis mediated by a highly conserved intrinsic internalization signal in the cytoplasmic domain of gp41 is suppressed in the presence of the Pr55gag precursor protein.
    J Virol. 1996 Oct;70(10):6547-56 PMID: 8794289
  18. Direct interaction between the envelope and matrix proteins of HIV-1.
    EMBO J. 1996 Nov 1;15(21):5783-8 PMID: 8918455
  19. Cell-dependent requirement of human immunodeficiency virus type 1 gp41 cytoplasmic tail for Env incorporation into virions.
    J Virol. 2000 May;74(10):4891-3 PMID: 10775630
  20. Antiserum to a synthetic peptide recognizes the HTLV-III envelope glycoprotein.
    Science. 1986 Mar 28;231(4745):1556-9 PMID: 3006246
  21. Induction of anti-HIV neutralizing antibodies by synthetic peptides.
    EMBO J. 1986 Nov;5(11):3065-71 PMID: 3466790
  22. Theoretically determined three-dimensional structures for amphipathic segments of the HIV-1 gp41 envelope protein.
    AIDS Res Hum Retroviruses. 1989 Feb;5(1):7-22 PMID: 2541749
  23. Rhesus macaques inoculated with molecularly cloned simian immunodeficiency virus.
    J Med Primatol. 1989;18(3-4):311-9 PMID: 2547965
  24. A general model for the transmembrane proteins of HIV and other retroviruses.
    AIDS Res Hum Retroviruses. 1989 Aug;5(4):431-40 PMID: 2788443
  25. The intracytoplasmic domain of the Env transmembrane protein is a locus for attenuation of simian immunodeficiency virus SIVmac in rhesus macaques.
    J Virol. 2000 Jul;74(13):5836-44 PMID: 10846063
  26. Core structure of gp41 from the HIV envelope glycoprotein.
    Cell. 1997 Apr 18;89(2):263-73 PMID: 9108481
  27. A leucine zipper-like sequence from the cytoplasmic tail of the HIV-1 envelope glycoprotein binds and perturbs lipid bilayers.
    Biochemistry. 1997 Apr 29;36(17):5157-69 PMID: 9136877
  28. Atomic structure of the ectodomain from HIV-1 gp41.
    Nature. 1997 May 22;387(6631):426-30 PMID: 9163431
  29. Isolation and characterization of two divergent infectious molecular clones of HIV type 1 longitudinally obtained from a seropositive patient by a progressive amplification procedure.
    AIDS Res Hum Retroviruses. 1997 Jun 10;13(9):743-50 PMID: 9171218
  30. Cell-cell fusion assay to study role of chemokine receptors in human immunodeficiency virus type 1 entry.
    Methods Enzymol. 1997;288:118-33 PMID: 9356991
  31. Novel antimicrobial peptides derived from human immunodeficiency virus type 1 and other lentivirus transmembrane proteins.
    Antimicrob Agents Chemother. 1997 Nov;41(11):2394-8 PMID: 9371339
  32. Interaction of endocytic signals from the HIV-1 envelope glycoprotein complex with members of the adaptor medium chain family.
    Virology. 1997 Nov 24;238(2):305-15 PMID: 9400603
  33. A membrane-proximal tyrosine-based signal mediates internalization of the HIV-1 envelope glycoprotein via interaction with the AP-2 clathrin adaptor.
    J Biol Chem. 1998 Jun 19;273(25):15773-8 PMID: 9624176
  34. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens.
    Science. 1998 Jun 19;280(5371):1884-8 PMID: 9632381
  35. A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding.
    Science. 1998 Jun 19;280(5371):1949-53 PMID: 9632396
  36. Importance of the intracytoplasmic domain of the simian immunodeficiency virus (SIV) envelope glycoprotein for pathogenesis.
    Virology. 1998 Dec 5;252(1):9-16 PMID: 9875311
  37. The crystal structure of the SIV gp41 ectodomain at 1.47 A resolution.
    J Struct Biol. 1999 Jun 15;126(2):131-44 PMID: 10388624
  38. Lentivirus-derived antimicrobial peptides: increased potency by sequence engineering and dimerization.
    J Antimicrob Chemother. 1999 Jul;44(1):33-41 PMID: 10459808
  39. Surface stability and immunogenicity of the human immunodeficiency virus envelope glycoprotein: role of the cytoplasmic domain.
    J Virol. 2004 Dec;78(24):13409-19 PMID: 15564451
  40. Part of the C-terminal tail of the envelope gp41 transmembrane glycoprotein of human immunodeficiency virus type 1 is exposed on the surface of infected cells and is involved in virus-mediated cell fusion.
    J Gen Virol. 2005 Jan;86(Pt 1):131-8 PMID: 15604440
  41. Multiple domains of the SIV Env protein determine virus replication efficiency and neutralization sensitivity.
    Virology. 2005 Feb 5;332(1):89-101 PMID: 15661143
  42. Antibody neutralization escape mediated by point mutations in the intracytoplasmic tail of human immunodeficiency virus type 1 gp41.
    J Virol. 2005 Feb;79(4):2097-107 PMID: 15681412
  43. The C-terminal tail of the gp41 transmembrane envelope glycoprotein of HIV-1 clades A, B, C, and D may exist in two conformations: an analysis of sequence, structure, and function.
    Virology. 2005 Jul 5;337(2):284-96 PMID: 15913700
  44. Regulation of human immunodeficiency virus type 1 envelope glycoprotein fusion by a membrane-interactive domain in the gp41 cytoplasmic tail.
    J Virol. 2005 Oct;79(19):12231-41 PMID: 16160149
  45. Virion envelope content, infectivity, and neutralization sensitivity of simian immunodeficiency virus.
    J Virol. 2005 Oct;79(19):12455-63 PMID: 16160173
  46. Mutations at the C-terminus of the simian immunodeficiency virus envelope glycoprotein affect gp120-gp41 stability on virions.
    Virology. 2006 Mar 30;347(1):217-25 PMID: 16380144
  47. Downregulation of human immunodeficiency virus type 1 Gag expression by a gp41 cytoplasmic domain fusion protein.
    Virology. 2006 May 10;348(2):418-29 PMID: 16472834
  48. Tail-interacting protein TIP47 is a connector between Gag and Env and is required for Env incorporation into HIV-1 virions.
    Proc Natl Acad Sci U S A. 2006 Oct 3;103(40):14947-52 PMID: 17003132
  49. Impact of natural polymorphism within the gp41 cytoplasmic tail of human immunodeficiency virus type 1 on the intracellular distribution of envelope glycoproteins and viral assembly.
    J Virol. 2007 Jan;81(1):125-40 PMID: 17050592
  50. The long cytoplasmic tail of gp41 is required in a cell type-dependent manner for HIV-1 envelope glycoprotein incorporation into virions.
    Proc Natl Acad Sci U S A. 2000 Jan 4;97(1):343-8 PMID: 10618420
  51. Genetic evidence for an interaction between human immunodeficiency virus type 1 matrix and alpha-helix 2 of the gp41 cytoplasmic tail.
    J Virol. 2000 Apr;74(8):3548-54 PMID: 10729129
  52. The cytoplasmic domain of simian immunodeficiency virus transmembrane protein modulates infectivity.
    J Virol. 1989 Oct;63(10):4395-403 PMID: 2778881
  53. Significance of premature stop codons in env of simian immunodeficiency virus.
    J Virol. 1989 Nov;63(11):4709-14 PMID: 2795718
  54. SIV adaptation to human cells.
    Nature. 1989 Oct 19;341(6243):573-4 PMID: 2677749
  55. The most highly amphiphilic alpha-helices include two amino acid segments in human immunodeficiency virus glycoprotein 41.
    Biopolymers. 1990 Jan;29(1):171-7 PMID: 2328285
  56. Retrovirus envelope glycoproteins.
    Curr Top Microbiol Immunol. 1990;157:187-253 PMID: 2203609
  57. A structural correlation between lentivirus transmembrane proteins and natural cytolytic peptides.
    AIDS Res Hum Retroviruses. 1991 Jun;7(6):511-9 PMID: 1657072
  58. Membrane interactions of synthetic peptides corresponding to amphipathic helical segments of the human immunodeficiency virus type-1 envelope glycoprotein.
    J Biol Chem. 1992 Apr 5;267(10):7121-7 PMID: 1551918
  59. Regulated expression of foreign genes in vaccinia virus under the control of bacteriophage T7 RNA polymerase and the Escherichia coli lac repressor.
    J Virol. 1992 May;66(5):2934-42 PMID: 1560532
  60. Genetic and biological comparisons of pathogenic and nonpathogenic molecular clones of simian immunodeficiency virus (SIVmac).
    AIDS Res Hum Retroviruses. 1992 Mar;8(3):395-402 PMID: 1571198
  61. Effects of deletions in the cytoplasmic domain on biological functions of human immunodeficiency virus type 1 envelope glycoproteins.
    J Virol. 1992 Jun;66(6):3306-15 PMID: 1583717
  62. Retained in vitro infectivity and cytopathogenicity of HIV-1 despite truncation of the C-terminal tail of the env gene product.
    Virology. 1992 Jul;189(1):167-77 PMID: 1604808
  63. Truncation of the human immunodeficiency virus type 1 transmembrane glycoprotein cytoplasmic domain blocks virus infectivity.
    J Virol. 1992 Nov;66(11):6616-25 PMID: 1357190
  64. An infectious molecular clone of an unusual macrophage-tropic and highly cytopathic strain of human immunodeficiency virus type 1.
    J Virol. 1992 Dec;66(12):7517-21 PMID: 1433527
  65. Mutations in the cytoplasmic domain of human immunodeficiency virus type 1 transmembrane protein impair the incorporation of Env proteins into mature virions.
    J Virol. 1993 Jan;67(1):213-21 PMID: 8416370
  66. Interaction of peptide fragment 828-848 of the envelope glycoprotein of human immunodeficiency virus type I with lipid bilayers.
    Biochemistry. 1993 Mar 30;32(12):3112-8 PMID: 8457572
  67. Truncation of the cytoplasmic domain of the simian immunodeficiency virus envelope glycoprotein increases env incorporation into particles and fusogenicity and infectivity.
    J Virol. 1993 May;67(5):2824-31 PMID: 8474176
  68. Alterations in cell membrane permeability by the lentivirus lytic peptide (LLP-1) of HIV-1 transmembrane protein.
    Virology. 1993 Sep;196(1):89-100 PMID: 8356808
  69. Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization.
    AIDS Res Hum Retroviruses. 1994 Apr;10(4):359-69 PMID: 7520721
  70. Virion incorporation of envelope glycoproteins with long but not short cytoplasmic tails is blocked by specific, single amino acid substitutions in the human immunodeficiency virus type 1 matrix.
    J Virol. 1995 Mar;69(3):1984-9 PMID: 7853546
  71. A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1.
    AIDS Res Hum Retroviruses. 1994 Dec;10(12):1651-8 PMID: 7888224
  72. Rescue of human immunodeficiency virus type 1 matrix protein mutants by envelope glycoproteins with short cytoplasmic domains.
    J Virol. 1995 Jun;69(6):3824-30 PMID: 7745730
  73. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120.
    J Virol. 2000 Sep;74(18):8358-67 PMID: 10954535
  74. Evidence for a stable interaction of gp41 with Pr55(Gag) in immature human immunodeficiency virus type 1 particles.
    J Virol. 2000 Oct;74(20):9381-7 PMID: 11000206
  75. Mutational analysis of conserved domains within the cytoplasmic tail of gp41 from human immunodeficiency virus type 1: effects on glycoprotein incorporation and infectivity.
    J Virol. 2000 Dec;74(24):11717-23 PMID: 11090171
  76. Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates.
    Structure. 2000 Dec 15;8(12):1329-39 PMID: 11188697
  77. The highly conserved C-terminal dileucine motif in the cytosolic domain of the human immunodeficiency virus type 1 envelope glycoprotein is critical for its association with the AP-1 clathrin adaptor [correction of adapter].
    J Virol. 2001 Mar;75(6):2982-92 PMID: 11222723
  78. C3d enhancement of antibodies to hemagglutinin accelerates protection against influenza virus challenge.
    Nat Immunol. 2000 Aug;1(2):127-31 PMID: 11248804
  79. Relationships between CD4 independence, neutralization sensitivity, and exposure of a CD4-induced epitope in a human immunodeficiency virus type 1 envelope protein.
    J Virol. 2001 Jun;75(11):5230-9 PMID: 11333905
  80. Identification of two sequences in the cytoplasmic tail of the human immunodeficiency virus type 1 envelope glycoprotein that inhibit cell surface expression.
    J Virol. 2001 Jun;75(11):5263-76 PMID: 11333908
  81. Domains in the simian immunodeficiency virus gp41 cytoplasmic tail required for envelope incorporation into particles.
    Virology. 2001 May 10;283(2):253-61 PMID: 11336550
  82. Enhanced avidity maturation of antibody to human immunodeficiency virus envelope: DNA vaccination with gp120-C3d fusion proteins.
    AIDS Res Hum Retroviruses. 2001 Jun 10;17(9):829-35 PMID: 11429124
  83. Recombinant measles viruses expressing altered hemagglutinin (H) genes: functional separation of mutations determining H antibody escape from neurovirulence.
    J Virol. 2001 Aug;75(16):7612-20 PMID: 11462033
  84. Cellular membrane-binding ability of the C-terminal cytoplasmic domain of human immunodeficiency virus type 1 envelope transmembrane protein gp41.
    J Virol. 2001 Oct;75(20):9925-38 PMID: 11559825
  85. Small variations in the length of the cytoplasmic domain of the simian immunodeficiency virus transmembrane protein drastically affect envelope incorporation and virus entry.
    AIDS Res Hum Retroviruses. 2001 Nov 20;17(17):1615-24 PMID: 11779349
  86. Truncation of the cytoplasmic domain induces exposure of conserved regions in the ectodomain of human immunodeficiency virus type 1 envelope protein.
    J Virol. 2002 Mar;76(6):2683-91 PMID: 11861835
  87. Mutation of the dominant endocytosis motif in human immunodeficiency virus type 1 gp41 can complement matrix mutations without increasing Env incorporation.
    J Virol. 2002 Apr;76(7):3338-49 PMID: 11884559
  88. Effect of point mutations in the N terminus of the lentivirus lytic peptide-1 sequence of human immunodeficiency virus type 1 transmembrane protein gp41 on Env stability.
    J Biol Chem. 2002 May 3;277(18):15363-75 PMID: 11859090
  89. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy.
    Antimicrob Agents Chemother. 2002 Jun;46(6):1896-905 PMID: 12019106
  90. Integrins: bidirectional, allosteric signaling machines.
    Cell. 2002 Sep 20;110(6):673-87 PMID: 12297042
Article Info
Journal
Virology
Abbr.
Virology
ISSN
0042-6822
DOI
10.1016/j.virol.2007.05.027
Published
2007-10-10
Epub
2007-00-19
Pages
102-16
Language
English
Region
United States
NLM ID
0110674
PMCID
PMC2034414
Subset
IM
Grants
NIAID NIH HHS · T32 AI049820-04 · United States
NIAID NIH HHS · R01 AI087533 · United States
NIAID NIH HHS · R21 AI070033 · United States
NIAID NIH HHS · R21 AI070033-02 · United States
NIAID NIH HHS · R21 AI070033-01 · United States
NIAID NIH HHS · T32 AI049820-05 · United States
NIAID NIH HHS · T32 AI049820 · United States
External Links
PubMed source DOI: 10.1016/j.virol.2007.05.027 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2